title: Hypertriglyceridemia and regulation of fibrinolytic activity.
abstract: A relation between elevated triglyceride (TG) levels and alterations of the fibrinolytic system has been recognized in studies of patients with coronary heart disease. In this investigation, the total fibrinolytic activity and the levels of specific components of the fibrinolytic system were evaluated in plasma samples from a highly selected group of patients with type IV hyperlipoproteinemia before and after a dietary treatment aimed at reducing TG levels. The fibrinolytic response of type IV patients was comparable to that of normolipidemic subjects, whereas tissue-type plasminogen activator antigen levels before and after venous occlusion (p less than 0.01) and resting plasminogen activator inhibitor-1 (PAI-1) antigen (p less than 0.01) and activity (p less than 0.01) were significantly higher in hypertriglyceridemic subjects compared with controls. After dietary treatment, a 22% reduction in TG levels was attained in type IV patients, with no appreciable modification of fibrinolytic parameters. The analysis of the single-patient data revealed a tendency toward normalization of PAI-1 levels only in those patients who showed a TG reduction greater than or equal to 20%. Very low density lipoproteins (VLDLs) from both normal and type IV patients concentration-dependently stimulated PAI-1 release by endothelial cells and HepG2 cells, with the effect of VLDL from type IV patients being more pronounced on HepG2 cells. The release of PAI-1 induced by VLDL in competent cells may thus account for the elevated levels of this antifibrinolytic protein that occur in hypertriglyceridemic patients.
authors.affiliation: E. Grossi Paoletti Center, University of Milan, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Mussoni
authors.forename: L
authors.initials: L
authors.lastname: Mannucci
authors.forename: M
authors.initials: M
authors.lastname: Sirtori
authors.forename: M
authors.initials: M
authors.lastname: Camera
authors.forename: P
authors.initials: P
authors.lastname: Maderna
authors.forename: L
authors.initials: L
authors.lastname: Sironi
authors.forename: E
authors.initials: E
authors.lastname: Tremoli
mesh_terms: D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000378:metabolism; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D005260:Female; D005342:Fibrinolysis; D006801:Humans; D006953:Hyperlipoproteinemia Type IV / Q000097:blood* / Q000178:diet therapy; D008079:Lipoproteins, VLDL / Q000494:pharmacology; D008113:Liver Neoplasms / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D015849:Plasminogen Inactivators / Q000378:metabolism; D012712:Serum Globulins / Q000378:metabolism; D010959:Tissue Plasminogen Activator / Q000378:metabolism; D014280:Triglycerides / Q000097:blood; D014407:Tumor Cells, Cultured
chemical_list: D008079:Lipoproteins, VLDL; D015849:Plasminogen Inactivators; D012712:Serum Globulins; D014280:Triglycerides; D010959:Tissue Plasminogen Activator